Results 21 to 30 of about 149,696 (169)

Defining the Debate on Controlling Biological Weapons [PDF]

open access: yes, 2001
Looks at the 1972 Biological and Toxins Weapons Convention, and outlines the series of measures being negotiated by the world community to create a strong, effective, and enforceable biological weapons ...
B. Alan Rosenberg
core  

Military potential of biological toxins

open access: yesJournal of Applied Biomedicine, 2014
Toxins are produced by bacteria, plants and animals for defense or for predation. Most of the toxins specifically affect the mammalian nervous system by interfering with the transmission of nerve impulses, and such toxins have the potential for misuse by the military or terrorist organizations.
Chu Wu   +5 more
openaire   +2 more sources

FoxO1 signaling in B cell malignancies and its therapeutic targeting

open access: yesFEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac   +3 more
wiley   +1 more source

The immunological interface: dendritic cells as key regulators in metabolic dysfunction‐associated steatotic liver disease

open access: yesFEBS Letters, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects nearly one‐third of the global population and poses a significant risk of progression to cirrhosis or liver cancer. Here, we discuss the roles of hepatic dendritic cell subtypes in MASLD, highlighting their distinct contributions to disease initiation and progression, and their ...
Camilla Klaimi   +3 more
wiley   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

open access: yesFEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Biology of killer yeasts [PDF]

open access: yes, 2010
Killer yeasts secrete proteinaceous killer toxins lethal to susceptible yeast strains. These toxins have no activity against microorganisms other than yeasts, and the killer strains are insensitive to their own toxins.
A. Santos, D. Marquina, J. Peinado
core   +2 more sources

Making tau amyloid models in vitro: a crucial and underestimated challenge

open access: yesFEBS Letters, EarlyView.
This review highlights the challenges of producing in vitro amyloid assemblies of the tau protein. We review how accurately the existing protocols mimic tau deposits found in the brain of patients affected with tauopathies. We discuss the important properties that should be considered when forming amyloids and the benchmarks that should be used to ...
Julien Broc, Clara Piersson, Yann Fichou
wiley   +1 more source

Design of microfluidic networks [PDF]

open access: yes, 2005
Microfluidics is a relatively new and fast growing research area in fluid mechanics. The devices in question are thin wafers containing etched or printed interconnecting channels through which fluids are pumped, which can mix and/or react at various ...
Billingham, John   +3 more
core  

Biologically Active Peptides in Physalia Toxin.

open access: yesExperimental Biology and Medicine, 1961
Summary and conclusionsThe crude toxin of Physalia nematocysts withstands lyophilization without significant loss of toxicity. Physalia toxin may be separated into component peptides by one-dimensional chromatography in 80% aqueous n-propanol. Each of the resultant peptides retains considerable toxicity for the fiddler crab, Uca pugilator.
Bradner W. Coursen   +2 more
openaire   +3 more sources

Refining the NaV1.7 pharmacophore of a class of venom‐derived peptide inhibitors via a combination of in silico screening and rational engineering

open access: yesFEBS Letters, EarlyView.
Venom peptides have shown promise in treating pain. Our study uses computer screening to identify a peptide that targets a sodium channel (NaV1.7) linked to chronic pain. We produced the peptide in the laboratory and refined its design, advancing the search for innovative pain therapies.
Gagan Sharma   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy